drugset / Trial / NCT03809429

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

NCT03809429

Phase 3 Completed 437 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.

Timeline

Start
2019-04-29
Primary completion
2022-02-16
Completion
2022-02-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetrorelix Other / unclassified
Subject Follitropin delta Protein / enzyme biologic
Subject Triptorelin Other / unclassified

Indications